Expression and clinical significance of miR-197 in the serum of prostate cancer patients

LI Li; WANG Sugui; YAN Yao; HAN Zhengxiang

doi:10.3969/j.issn.2096-3882.2019.09.16

Journal of Xuzhou Medical University > 2019 > 39(9): 691-694. > DOI: 10.3969/j.issn.2096-3882.2019.09.16

LI Li, WANG Sugui, YAN Yao, HAN Zhengxiang. Expression and clinical significance of miR-197 in the serum of prostate cancer patients[J]. Journal of Xuzhou Medical University, 2019, 39(9): 691-694. DOI: 10.3969/j.issn.2096-3882.2019.09.16

Citation:

PDF (585 KB)

Expression and clinical significance of miR-197 in the serum of prostate cancer patients

1. School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China;
2. Department of Urology, Huai'an Hospital Affiliated of Xuzhou Medical University, Huai'an, Jiangsu 223002;
3. Department of Urology, Huaiyin Hospital of Huai'an, Huai'an, Jiangsu 223300

More Information

Received Date: June 16, 2019
Revised Date: August 28, 2019

Graphical Abstract

Abstract

Abstract

Objective To investigate the expression of microRNA-197 (miR-197) in the serum of prostate cancer patients and its clinical significance. Methods Real-time fluorescence quantitative polymerase chain reaction (qPCR) was used to detect the relative expression of serum miR-197 in 48 prostate cancer patients, 48 patients with benign prostatic hyperplasia and 48 healthy subjects. The relationship between the relative expression of serum miR-197 and clinicopathological characteristics was analyzed. The receiver operating characteristic (ROC) curve was plotted to analyze the sensitivity and specificity of serum miR-197 in the diagnosis of prostate cancer. Results The level of serum miR-197 in prostate cancer patients was higher than that in benign prostatic hyperplasia and healthy subjects (P<0.05). However, there was no significant difference in the level of serum miR-197 between benign prostatic hyperplasia patients and healthy subjects (P>0.05). The level of serum miR-197 was significantly correlated with clinical pathological stage, Gleason score and bone metastasis of prostate cancer (P<0.05), rather than age and prostate specific antigen (P>0.05). ROC curve showed that miR-197 could differentiate prostate cancer from benign prostatic hyperplasia and healthy subjects, with the area under the curve was 0.828 (95% CI: 0.794-0.919) and 0.809 (95% CI: 0.746-0.918), respectively. Conclusions The high expression of miR-197 in the serum of prostate cancer patients is related to the progression of prostate cancer, and can be used as a marker to determine the prognosis of prostate cancer.
- microRNA-197,
- serum,
- prostate cancer

FullText(HTML)

References (15)

References

[1]	叶定伟,朱耀. 中国前列腺癌的流行病学概述和启示[J].中华外科杂志,2015,53(4):249-252. DOI: 10.3760/cma.j.issn.0529-5815.2015.04.003.
[2]	李树平,贺凯,阳大庆,等. 尿肌氨酸与血清PSA在前列腺癌早期诊断中的意义[J].中国男科学杂志.2017,31(2): 33-35. DOI: 10.3969/j.issn.1008-0848.2017.02.007
[3]	王苏贵, 吴自余, 李强, 等. 微小RNA活性分析法筛选前列腺癌去势抵抗转化相关微小RNA的实验研究[J]. 中华解剖与临床杂志, 2018, 23(6): 538-542. DOI: 10.3760/cma.j.issn.2095-7041.2018.06.017
[4]	丁翔,崔凤梅,侯建全,等. 前列腺癌患者血清微小RNA表达谱的初步研究[J].中华泌尿外科杂志,2015,36(3):225-228. DOI: 10.3760/cma.j.issn.1000-6702.2015.03.018
[5]	Shi XB, Xue LR. Yang J, et al.An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells[J]. Proc Natl Acad Sci USA, 2007,104(50):19983-19988. DOI: 10.1073/pnas.0706641104
[6]	Li T, Li D, Sha JJ, et al. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells[J]. Biochem Biophys Res Commun,2009, 383(3): 280-285. DOI: 10.1016/j.bbrc.2009.03.077.
[7]	Galardi S, Mercatelli N, Giorda E, et al.miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1[J]. J Biol Chem,2007,282:23716-23724. DOI: 10.1074/jbc.M701805200
[8]	Zhu J, Wang SG, Zhang W, et al. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network[J]. Oncotarget, 2015,6(41):43819-43830. DOI: 10.18632/oncotarget.6102.
[9]	Xu B,Wang N,Wang XH,et al. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer[J]. Prostate,2012,72(11):1171-1178. DOI: 10.1002/pros.22466.
[10]	Fujita Y,Kojima K,Hamada N,et al.Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells[J].Biochem Biophys Res Commun,2008,377(1):114-119. DOI: 10.1159/000494004.
[11]	Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers[J]. Mol Cancer, 2007, 6(1): 60. DOI: 10.1186/1476-4598-6-60.
[12]	Heegaard NHH, Schetter AJ, Welsh JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer[J]. Int J Cancer, 2012, 130(6): 1378-1386. DOI: 10.1002/ijc.26153.
[13]	叶维霞,郭建红. MiR-197在结肠癌细胞及组织中表达及其意义[J].医药前沿,2018,8(17):197-198. DOI: 2095-1752(2018)17-0197-02.
[14]	张振华,张伟,刘伟良,等. 非小细胞肺癌血清miR-197和miR-203的表达及意义[J].现代肿瘤医学,2016,24(19):3057-3059. DOI: 10.3969/j.issn.1672-4992.2016.19.015
[15]	陈晓敏,曹国平,陈琪. 甲状腺癌患者血清miR-197异常高表达及其意义[J].浙江临床医学,2014,16(6):934-935.

Cited By

Cited by

Periodical cited type(1)

叶维霞，黄学平，郭建红，龙维利. miR-197靶向调节CD82对结肠癌细胞侵袭转移的影响. 西部医学. 2020(09): 1310-1313 .

Other cited types(0)

Get Citation

PDF

XML

Article views (1105) PDF downloads (88) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Expression and clinical significance of miR-197 in the serum of prostate cancer patients

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content